Fernández-Nebro Antonio, Rúa-Figueroa Íñigo, López-Longo Francisco J, Galindo-Izquierdo María, Calvo-Alén Jaime, Olivé-Marqués Alejandro, Ordóñez-Cañizares Carmen, Martín-Martínez María A, Blanco Ricardo, Melero-González Rafael, Ibáñez-Rúan Jesús, Bernal-Vidal José Antonio, Tomero-Muriel Eva, Uriarte-Isacelaya Esther, Horcada-Rubio Loreto, Freire-González Mercedes, Narváez Javier, Boteanu Alina L, Santos-Soler Gregorio, Andreu José L, Pego-Reigosa José M
On behalf of EAS-SER (Systemic Diseases Study Group of the Spanish Society of Rheumatology) From the UGC Reumatología (AFN), Instituto de Investigación Biomédica (IBIMA), Hospital Regional Universitario de Málaga, Universidad de Málaga, Málaga; Department of Rheumatology (ÍRF), Dr Negrín General University Hospital, Las Palmas de Gran Canaria, Gran Canaria; Department of Rheumatology (FLL), Gregorio Marañón University Hospital; Department of Rheumatology (MGI), Doce de Octubre University Hospital, Madrid; Department of Rheumatology (JCA), Sierrallana Hospital, Torrelavega; Department of Rheumatology (AOM), Germans Trías i Pujol University Hospital, Badalona; UGC Reumatología (COC), Instituto de Investigación Biomédica (IBIMA), Hospital Regional Universitario de Málaga, Universidad de Málaga, Málaga; Research Unit of Spanish Society of Rheumatology (MMM), Madrid; Department of Rheumatology (RB), Marqués de Valdecilla University Hospital, Santander; Department of Rheumatology (RMG), Hospital Complex of Ourense, Ourense; Department of Rheumatology (JIR), POVISA Hospital, Vigo; Department of Rheumatology (JBV), Alicante General University Hospital, Alicante; Department of Rheumatology (ETM), La Princesa University Hospital, Madrid; Department of Rheumatology (EUI), Donosti University Hospital, Guipuzcoa; Department of Rheumatology (LHR), Navarra Hospital, Pamplona; Department of Rheumatology (MFG), Juan Canalejo University Hospital, La Coruña; Department of Rheumatology (JN), Bellvitge University Hospital, Barcelona; Department of Rheumatology (ALB), Ramón y Cajal University Hospital, Madrid; Department of Rheumatology (GSS), Marina Baixa University Hospital, Villajoyosa, Alicante; Department of Rheumatology (JAS), Puerta del Hierro-Majadahonda Hospital, Madrid; and University Hospital Complex (JMPR), Instituto de Investigación Biomédica de Vigo (IBIV), Vigo, Spain.
Medicine (Baltimore). 2015 Jul;94(29):e1183. doi: 10.1097/MD.0000000000001183.
This article estimates the frequency of cardiovascular (CV) events that occurred after diagnosis in a large Spanish cohort of patients with systemic lupus erythematosus (SLE) and investigates the main risk factors for atherosclerosis. RELESSER is a nationwide multicenter, hospital-based registry of SLE patients. This is a cross-sectional study. Demographic and clinical variables, the presence of traditional risk factors, and CV events were collected. A CV event was defined as a myocardial infarction, angina, stroke, and/or peripheral artery disease. Multiple logistic regression analysis was performed to investigate the possible risk factors for atherosclerosis. From 2011 to 2012, 3658 SLE patients were enrolled. Of these, 374 (10.9%) patients suffered at least a CV event. In 269 (7.4%) patients, the CV events occurred after SLE diagnosis (86.2% women, median [interquartile range] age 54.9 years [43.2-66.1], and SLE duration of 212.0 months [120.8-289.0]). Strokes (5.7%) were the most frequent CV event, followed by ischemic heart disease (3.8%) and peripheral artery disease (2.2%). Multivariate analysis identified age (odds ratio [95% confidence interval], 1.03 [1.02-1.04]), hypertension (1.71 [1.20-2.44]), smoking (1.48 [1.06-2.07]), diabetes (2.2 [1.32-3.74]), dyslipidemia (2.18 [1.54-3.09]), neurolupus (2.42 [1.56-3.75]), valvulopathy (2.44 [1.34-4.26]), serositis (1.54 [1.09-2.18]), antiphospholipid antibodies (1.57 [1.13-2.17]), low complement (1.81 [1.12-2.93]), and azathioprine (1.47 [1.04-2.07]) as risk factors for CV events. We have confirmed that SLE patients suffer a high prevalence of premature CV disease. Both traditional and nontraditional risk factors contribute to this higher prevalence. Although it needs to be verified with future studies, our study also shows-for the first time-an association between diabetes and CV events in SLE patients.
本文评估了西班牙一个大型系统性红斑狼疮(SLE)患者队列确诊后心血管(CV)事件的发生频率,并调查了动脉粥样硬化的主要危险因素。RELESSER是一个全国性的、基于医院的SLE患者多中心登记处。这是一项横断面研究。收集了人口统计学和临床变量、传统危险因素的存在情况以及CV事件。CV事件定义为心肌梗死、心绞痛、中风和/或外周动脉疾病。进行多因素逻辑回归分析以调查动脉粥样硬化的可能危险因素。2011年至2012年,纳入了3658例SLE患者。其中,374例(10.9%)患者至少发生过一次CV事件。在269例(7.4%)患者中,CV事件发生在SLE诊断之后(86.2%为女性,年龄中位数[四分位间距]为54.9岁[43.2 - 66.1],SLE病程为212.0个月[120.8 - 289.0])。中风(5.7%)是最常见的CV事件,其次是缺血性心脏病(3.8%)和外周动脉疾病(2.2%)。多因素分析确定年龄(比值比[95%置信区间],1.03[1.02 - 1.04])、高血压(1.71[1.20 - 2.44])、吸烟(1.48[1.06 - 2.07])、糖尿病(2.2[1.32 - 3.74])、血脂异常(2.18[1.54 - 3.09])、神经狼疮(2.42[1.56 - 3.75])、瓣膜病(2.44[1.34 - 4.26])、浆膜炎(1.54[1.09 - 2.18])、抗磷脂抗体(1.57[1.13 - 2.17])、低补体(1.81[1.12 - 2.93])和硫唑嘌呤(1.47[1.04 - 2.07])为CV事件的危险因素。我们已证实SLE患者过早发生CV疾病的患病率很高。传统和非传统危险因素均导致了这一较高的患病率。尽管需要未来的研究加以验证,但我们的研究也首次显示了SLE患者中糖尿病与CV事件之间的关联。